You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Positive MHRA decision for Briviact

UCB has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a label extension for seizure treatment, Briviact – also known as brivaracetam.